A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

DOI10.1002/SIM.9242zbMATH Open1545.62473MaRDI QIDQ6622241

Rui Tang, Jin Xu, Rongji Mu, Ying Yuan, Scott Kopetz

Publication date: 22 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

immunotherapyBayesian adaptive designrisk-benefit tradeoffplatform trialoptimal biological dose

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Title not available (Why is that?)
• Title not available (Why is that?)
• Title not available (Why is that?)
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• A weakly informative default prior distribution for logistic and other regression models
• Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• A Bayesian Phase I/II Trial Design for Immunotherapy
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Bayesian Analysis of Binary and Polychotomous Response Data
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
• A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
• gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points
• A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point

This page was built for publication: A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6622241)